Based on the available evidence, retatrutide liver fat reduction may be of particular relevance to several patient populations, should the drug receive regulatory approval
(2023) "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial" The Lancet, 402(10403) 4
Probably The role of GLP-1s in preventing and managing cardiometabolic conditions may reduce future health care expenditures by avoiding doctors visits, emergency room care, additional medications, and productivity loss
20 HartyP
(accessed May 2013) 64.Boehringer Ingelheim Pharmaceuticals, Inc
This includes protein, fiber, vitamins and minerals